Menu
Home
Forums
Forums
Quick Links
Search Forums
Recent Posts
job listings
catering
whistleblower info
legal help
advertise on CP
submit press release
Menu
Log in
Sign up
Search titles only
Posted by Member:
Separate names with a comma.
Newer Than:
Search this thread only
Search this forum only
Display results as threads
More...
Useful Searches
Recent Posts
Cafepharma Message Boards | Pharma Sales, Device Sales, Lab Sales
Home
Forums
>
Pharma/Biotech Companies
>
Acorda Therapeutics
>
Scopia
>
Reply to Thread
Name:
Verification:
Answer the above question:
(
CustomImgCaptcha
By
Surrey Forum
)
Message:
<p>[QUOTE="anonymous, post: 6015390"]Easy there my little propagandist friend. To imply Scopia is in this solely because of the value of inhaled LD is a bit disingenuous. They are trying to recover an investment from a different ACOR. You remember the one that had a few more molecules in the pipeline and some patent protection on their only revenue generating asset? </p><p><br /></p><p>Of course they want buyers to view this asset as a blockbuster to get money from a naive BD team that needs a deal. If they were confident of $1 billion, it would make more sense for ACOR to keep it. </p><p><br /></p><p>Here’s the problem, there has never been a modified release neurology product that has done close to what you are claiming inhaled LD will do. It has barely happened in more primary care conditions, especially in the last five years.</p><p><br /></p><p>Quite the quandary: sell it for a reasonable price and only do $225-$275M peak or raise the price (limiting uptake), gouge the patient and insurer,pay higher rebates to post anything > $350M. Kind of flies in the face of the patient centric ideology. One more little issue, all those rebate costs come off the bottom line, so it really isn’t much of a gain other than on paper.</p><p><br /></p><p>Enjoy the sale[/QUOTE]</p><p><br /></p>
[QUOTE="anonymous, post: 6015390"]Easy there my little propagandist friend. To imply Scopia is in this solely because of the value of inhaled LD is a bit disingenuous. They are trying to recover an investment from a different ACOR. You remember the one that had a few more molecules in the pipeline and some patent protection on their only revenue generating asset? Of course they want buyers to view this asset as a blockbuster to get money from a naive BD team that needs a deal. If they were confident of $1 billion, it would make more sense for ACOR to keep it. Here’s the problem, there has never been a modified release neurology product that has done close to what you are claiming inhaled LD will do. It has barely happened in more primary care conditions, especially in the last five years. Quite the quandary: sell it for a reasonable price and only do $225-$275M peak or raise the price (limiting uptake), gouge the patient and insurer,pay higher rebates to post anything > $350M. Kind of flies in the face of the patient centric ideology. One more little issue, all those rebate costs come off the bottom line, so it really isn’t much of a gain other than on paper. Enjoy the sale[/QUOTE]
Your name or email address:
Do you already have an account?
No, create an account now.
Yes, my password is:
Forgot your password?
Stay logged in
Cafepharma Message Boards | Pharma Sales, Device Sales, Lab Sales
Home
Forums
>
Pharma/Biotech Companies
>
Acorda Therapeutics
>
Scopia
>
Cafepharma Message Boards | Pharma Sales, Device Sales, Lab Sales
Home
Forums
>
Pharma/Biotech Companies
>
Acorda Therapeutics
>
Scopia
>